ASAndrás Süle

András Süle

*This is an algorithmically generated author record based on publicly available information.

András Süle has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Accelerating biosimilar adoption by empowering hospital pharmacists: a dialogue between emerging markets and European hospital pharmacists

    by Nenad Miljković, András Süle, Ana Lozano Blázquez, Despoina Makridaki, Tjalling van der Schors, Håvard Kirkevold, Romain De Jorna, Gonzalo Marzal Lopez


  • Open Access

    Investigation of the hospital pharmacy profession in Europe

    by Darija Kuruc Poje, Raymond William Fitzpatrick, Claire Stevens, Carl Machin, Jonathan Underhill, Petr Horák, Aida Batista, András Süle, Nenad Miljković, Claudia Plesan, et al.

    Objective From 1995, the European Association of Hospital Pharmacists (EAHP) has regularly investigated the progress of the hospital pharmacy profession in Europe, and identified key barriers and drivers of this. The most recent ‘Investigation of the Hospital Pharmacy Profession in Europe’ was conducted from November 2022 to March 2023. Methods The online questionnaire was sent to all hospital pharmacies in EAHP member countries. The investigation was drafted using the same questions as the 2015 baseline survey. Where possible and relevant, responses were compared with the data from previous surveys that monitored the implementation of the EAHP statements. Keele University, Centre for Medicines Optimisation, School of Pharmacy and Bioengineering, UK analysed the data. Results The overall number of responses was 653, with a better response rate of 19% compared with 14% in 2018 statements survey. The findings indicated that participating hospital pharmacies have similar characteristics to previous surveys. Section 1 (Introductory statements and governance), section 2 (Selection, procurement and distribution), section 3 (Production and compounding), section 5 (Patient safety and quality assurance) questions were generally answered positively, with results ranging from 52% to 90%. However, results for section 4 (Clinical pharmacy services) returned lower levels of positivity, with responses from 8 of the 15 questions being less than 60%. When asked what is preventing hospital pharmacists from achieving implementation of these activities, most answers were limited capacity, not considered to be a priority by managers, or other healthcare professionals do this. The last section focused on self-assessment and action planning, with fewer than 50% of positive responses; COVID-19 preparedness and vaccines with mixed positive and negative responses. Furthermore, implementation of the falsified medicines directive impacted the medication handling processes in 50% or more of the answers. Regarding sustainability, the majority (59%) of respondents felt a greater focus should be on sustainability from an organisational or management perspective. Conclusion Results offer valuable insights into the hospital pharmacy profession throughout Europe. While there have been improvements in certain areas, challenges remain, particularly in implementing clinical pharmacy services. The findings provide a foundation for further dialogue, advocacy, and strategic planning to advance the role of hospital pharmacists and enhance patient care in Europe’s healthcare systems.


  • Open Access

    Results of EAHP’s 2023 shortages survey

    by Nenad Miljković, Piera Polidori, Daniele Leonardi Vinci, Darija Kuruc Poje, Despina Makridaki, Stephanie Kohl, András Süle

    Aims and objective The aim of the European Association of Hospital Pharmacists (EAHP)’s 2023 shortages survey was to collect data on causes and mitigation strategies of shortages of medicines and medical devices and their impact on patient care. The survey targeted hospital pharmacists (HPs), physicians (PHYs), nurses (NRS) and other healthcare professionals (OHCPs). A separate set of questions addressed patients (PTNs). Methods A 49-question survey was carried out by a team at EAHP, collecting information from European HPs, PTNs, NRS, PHYs and OTHCs on shortages of medicines and medical devices in their respective countries. The survey ran from 27 February to 19 May 2023. The results were analysed by EAHP. Results There were 1497 HP responses to the 2023 survey. While 95% (n=1429) of HPs and 86% (n=127) of OHCPs consider medicine shortages an ongoing problem, 84% (n=48) of PHYs and 68% (n=15) of NRS also agreed. Shortages of active pharmaceutical ingredients (77%, n=1148), manufacturing (67%, n=1007) and supply chain problems (50%, n=752) are major causes of shortages according to HPs as well as NRS and OHCPs; PHYs (49%, n=18) consider pricing to be the driver. More than 60% (n=765) of HPs, 55% (n=11) of NRS, 57% (n=30) of PHYs and 46% (n=56) of OHCPs experienced shortages of medical devices in 2022. Antimicrobials were most affected, according to all respondent groups, followed by analgesics, anaesthetics, cardiovascular and paediatric medicines. HPs (59%, n=269), NRS (57%, n=4), OHCPs (56%, n=37) and PHYs (54%, n=14) consider delays in care as the main consequence of medication shortages. Conclusions Shortages of medicines and medical devices affect healthcare services and patient care. Increased transparency and access to information regarding ongoing and emerging shortages as well as better preparedness of healthcare professionals is crucial to their effective management.


  • Hospital pharmacy workforce

    by Petr Horák, Despina Makridaki, Piera Polidori, András Süle, Louis Bertin, Stephanie Kohl


  • Digital health

    by Tjalling van der Schors, Ana Lozano-Blázquez, Darija Kuruc Poje, Nenad Miljković, András Süle, Stephanie Kohl

    In order for healthcare electronic services to be safe, effective and add genuine value to the system, the European Association of Hospital Pharmacists (EAHP) believes that these services should be developed in close collaboration with healthcare professionals including hospital pharmacists and patients. To ensure that hospital pharmacists are capable of fully using all the digitalisation benefits for their patients and the functioning of the healthcare system, investments in infrastructure, software and hardware are needed across Europe.